Can we stop type 1 diabetes before it starts? I’m joined by Sam Reich, CEO of SAB Bio, and Dr. Mike Haller, a leading T1D researcher, to explore an innovative new therapy called SAB-142. Unlike traditional thymoglobulin, which is derived from rabbits, SAB’s therapy uses a fully human version produced by genetically engineered cows—potentially eliminating harmful side effects like serum sickness. We unpack how this treatment could delay or prevent the onset of type 1 diabetes and how it builds on research behind Teplizumab. Plus, we talk about the pivotal role NIH funding plays in advancing diabetes innovation. If you're curious about the future of diabetes prevention, you won’t want to miss this.

Learn about Omnipod 5 (today's sponsor)*

T1D Exchange Registry Sign up  (US residents only)

Watch This Episode On Youtube

Join our Newsletter | Support us on Patreon 

Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook

DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care. 

*10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.